Insiders Of INmune Bio Are Up 38% On Their US$714.9k Purchase
Insiders Of INmune Bio Are Up 38% On Their US$714.9k Purchase
INmune Bio, Inc. (NASDAQ:INMB) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 35%, resulting in a US$61m rise in the company's market capitalisation, translating to a gain of 38% on their initial investment. In other words, the original US$714.9k purchase is now worth US$983.2k.
在過去一年中購買股票的InMune Bio, Inc.(納斯達克股票代碼:INMB)內部人士上週獲得了豐厚的回報。該股上漲了35%,導致該公司的市值增長了6100萬美元,這意味着他們的初始投資收益了38%。換句話說,最初購買的714.9萬美元現在價值983.2萬美元。
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
儘管在長期投資方面,內幕交易並不是最重要的事情,但我們確實認爲密切關注內部人士的所作所爲是完全合乎邏輯的。
INmune Bio Insider Transactions Over The Last Year
去年的InMune Bio內幕交易
Notably, that recent purchase by Scott Juda is the biggest insider purchase of INmune Bio shares that we've seen in the last year. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$11.29. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
值得注意的是,斯科特·朱達最近的一次收購是我們去年對InMune Bio股票的最大一次內幕收購。儘管我們希望看到內幕買盤,但我們注意到,此次大宗收購的價格遠低於最近的11.29美元。儘管這確實表明內部人士認爲該股在較低的價格下被低估,但這筆交易並沒有告訴我們他們對當前價格的看法。
While INmune Bio insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
儘管InMune Bio內部人士在去年購買了股票,但他們並沒有賣出。下圖顯示了去年的內幕交易(公司和個人)。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
還有很多其他公司有內部人士購買股票。你可能不想錯過這份業內人士正在收購的成長型公司的免費名單。
INmune Bio Insiders Bought Stock Recently
InMune Bio內部人士最近購買了股票
Over the last three months, we've seen significant insider buying at INmune Bio. Overall, four insiders shelled out US$666k for shares in the company -- and none sold. This could be interpreted as suggesting a positive outlook.
在過去的三個月中,我們看到了InMune Bio的大量內幕收購。總體而言,四位內部人士花了66.6萬美元購買了該公司的股票,但沒有人出售。這可以解釋爲前景樂觀。
Insider Ownership Of INmune Bio
InMune Bio的內部所有權
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that INmune Bio insiders own 24% of the company, worth about US$51m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
許多投資者喜歡查看公司內部人士擁有多少股份。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。看來InMune Bio內部人士擁有該公司24%的股份,價值約5100萬美元。這種內部所有權水平不錯,但還沒有特別突出。這無疑表明了一定程度的一致性。
What Might The Insider Transactions At INmune Bio Tell Us?
InMune Bio的內幕交易能告訴我們什麼?
It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Insiders likely see value in INmune Bio shares, given these transactions (along with notable insider ownership of the company). So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Our analysis shows 4 warning signs for INmune Bio (1 is a bit unpleasant!) and we strongly recommend you look at them before investing.
看到最近的內幕收購無疑是積極的。我們還從內幕交易的長期前景中汲取信心。但是,我們注意到,該公司在過去十二個月中沒有盈利,這使我們謹慎行事。鑑於這些交易(以及該公司顯著的內部所有權),內部人士可能會看到InMune Bio股票的價值。因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解這家公司面臨的風險。我們的分析顯示 InMune Bio 有 4 個警告信號(1 個有點不愉快!)我們強烈建議您在投資之前先看看它們。
Of course INmune Bio may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,InMune Bio可能不是最值得購買的股票。因此,您可能希望看到這個免費的高質量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。